Drugs / JNJ-39393406
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 missed | ||||||
| Phase 1 | NCT01556217 | Sep → Nov 2010 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT01137799 | Aug 2009 → Mar 2011 | Alzheimer disease, schizophrenia | Janssen Pharmaceutica N.V., Belgium | Terminated | Missed primary Stop: Enrollment |
| Phase 1 | NCT01986491 | May → Aug 2009 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT02023255 | Jan → Jun 2009 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02677207 | Feb 2016 → May 2017 | depressive disorder | Tangent Data | Completed | No outcome recorded |
| Phase 2 | NCT02217527 | Nov 2014 → Jul 2017 | — | Chengappa, K.N. Roy, MD | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-39393406 | “We aim to test the proof of principal that an alpha-7 PAM drug, JNJ-39393406, promotes smoking cessation when compared to placebo.” NCT02217527 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator” CHEMBL3545291 ↗ |
| Modality | Small molecule | — CHEMBL3545291 ↗ |
| Route | Oral | “single oral doses of JNJ-39393406” NCT01137799 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator” CHEMBL3545291 ↗ |